OTFC Tax Type Combination AbsId 275 OFML Tax Formula Master Table AbsId 276 OCNA CNAE Code AbsId 278 OTSI Sales Tax Invoice DocEntry 280 OTPI Purchase Tax Invoice DocEntry 281 OCCD Cargo Customs Declaration Numbers CCDNum 283 ORSC Resources ResCode 290 ORSG Resource Properties ResTypCod 291...
Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient drug or as part of a combination product. These products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but ...
The clinical trial approval of ICP-248 in combination with orelabrutinib as a first-line therapy for CLL/SLL in March 2024. In the U.S., the IND was cleared in January 2024. ICP-248 willbecome an important asset for the Company’s globalization. ICP-248 is a novel, orally bioavailable...
net of tax Total comprehensive income Dividends Capital transaction under common control Effect of business combination Disposal of treasury stock Stock option activities Others Total transactions with owners Balance at September 30, 2013 111,070 - 723,361 - 4,094,359 - (7,617,184) - 111,552,...
A combination of SMC models and naïve Bayesian forecasts the performance of e-commerce website customers. The new model, the Naive Bayesian method, outperforms the SMC model. The shopper movement level of an online business site utilizing the non-authoritative relationship and the SMC model. ...
In December 2020, Allogene announced that the FDA had approved the IND for ALLO-715 in combination with nirogacestat, a SpringWorks Therapeutics’ investigational gamma secretase inhibitor, in patients with r/r MM. ALLO-501 and ALLO-501A in relapsed/refractory non-H...
CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy. We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA...
In addition, the authors’ results suggest that there is no optimal dwell time for destination charging; rather, it is the combination of various parameters such as dwell time, arrival time, time of departure and demand at location, that determines if a particular location is economically viable...
Even though the use of multiple tools and techniques in quality improvement and risk management processes is relatively common and even recommended by ISO, 2018, ISO, 2019, we have not identified in the existing literature a combination of process mapping, brainstorming, bow-tie and FMEA in heal...
Continuously proceeded with a Phase I trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and relapsed or refractory NHL. We will explore the combination of CM369 with other immunotherapies in various c...